Drug intelligence / Profile preview

HODO-2225

Development stage: Unknown
Lead developer: Hyundai Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**HODO-2225** is a Hyundai Pharmaceutical fixed-dose oral combination candidate reported to contain empagliflozin, ezetimibe, and rosuvastatin. It combines sodium-glucose cotransporter 2 inhibition to increase urinary glucose excretion, inhibition of intestinal Niemann-Pick C1-like 1-mediated cholesterol absorption, and competitive inhibition of HMG-CoA reductase to reduce cholesterol synthesis. The program has entered Phase 1 clinical development in South Korea as a cardiometabolic therapy.

Targets

NPC1L1 (Niemann-pick C1-Like 1 transporter)SGLT2 (Sodium-glucose cotransporter protein subunit 2)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on HODO-2225.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HODO-2225.

Explore the full profile